UAE ADPKD (Autosomal dominant polycystic kidney disease) Therapeutic Market Report 2022 to 2030

UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

$ 3999

The UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $6 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $9 Mn by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Reta, Regulus, and AceLink Therapeutics, among others

ID: IN10AEPH425 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Riddhi Solanki

Buy Now

UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $6 Mn in 2022 and is projected to reach US $9 Mn in 2030, exhibiting a CAGR of 6.8% during the forecast period.

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition caused by mutations in the PKD1 and PKD2 genes, leading to the formation of fluid-filled cysts in the kidneys. In most cases, these cysts enlarge, causing renomegaly and eventually leading to kidney failure. Common symptoms of ADPKD include pain, fatigue, urinary tract infections, and others. While there is no cure for ADPKD, several treatment approaches primarily focus on managing symptoms and limiting disease progression. The only available drug for ADPKD is tolvaptan (Jinarc) manufactured by Otsuka Pharmaceuticals, which acts as a vasopressin blocker and has been shown to reduce cyst formation in some patients. Other therapeutic options include pain management, lifestyle modifications, blood pressure treatments, and the use of antibiotics to treat infections associated with the condition.

Estimates that the incidence of ADPKD is around 2-4 per 10,000 individuals in the UAE. 2.43% of these ADPKD patients are currently undergoing hemolysis, indicating the severity of the disease. The market is therefore driven by major factors like increased incidence of ADPKD cases, government initiatives through supportive policies, and increased awareness of the population. However, conditions such as high costs of advanced treatment, a lack of specialised healthcare professionals, and others hinder the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in the incidence of ADPKD: Estimates in the UAE suggest that the incidence of ADPKD is roughly between 2-4/10,000 individuals. Studies also suggest that 2.43% of ADPKD patients account for those undergoing hemolysis. These estimates are expected to create a huge pool of patients requiring treatment, resulting in the growth of the market.

Government initiatives: Government initiatives and supportive policies such as the Thiqa and Saada programs are helping to bridge the gap in affordability and accessibility. The stable economic conditions of the country further allow the exploration of gene therapy and gene editing as potential options, which results in market expansion.

Increased awareness: Groups such as the Abu Dhabi PDK support group, which works on awareness and diagnosis, actively push for research funding, enhanced healthcare access, and public awareness. Their activities stimulate market growth by encouraging early detection, initiating treatment, and bolstering disease management practices.

Market Restraints

High costs of treatment: Treatments for ADPKD, such as Tolvaptan, can be costly, causing a considerable financial burden on both patients and the healthcare system. This can restrict treatment access, especially for those with inadequate insurance coverage or limited financial means, distorting the growth of the UAE market.

Health System Challenges: The UAE’s healthcare system is progressing, yet discrepancies in accessing specialized care and advanced treatments may persist between urban and rural regions. Relying on imported medications could face fluctuating expenses and potential disruptions in the supply chain, restricting the growth of the market.

Access to specialist care: Even with improvements in healthcare infrastructure, discrepancies in accessing nephrologists and specialized ADPKD care persist in certain areas of the UAE. This limitation can hinder prompt diagnosis, optimal treatment commencement, and holistic care for patients, which distorts the growth of the market.

Regulatory challenges: Although advancements in medication approval and market entry regulations are underway, manoeuvring through the system might be complex, potentially delaying the launch of innovative ADPKD treatments. Establishing a strong pharmacovigilance system to oversee the safety and effectiveness of ADPKD medications is lacking.

Healthcare Policies and Regulatory Landscape

In the UAE, healthcare policy and regulations are overseen by both federal and emirate-level agencies. The Ministry of Health and Prevention serves as the primary federal regulatory body, while the Department of Health (DOH) in Abu Dhabi, the Dubai Health Authority (DHA), and the recently established Emirates Health Authority (EHA) are key emirate-level authorities.

The UAE government has prioritized the healthcare sector and has recently made substantial advancements. With a strong healthcare system and a focus on clinical research, the nation is positioned to become a regional hub for healthcare.

The licensure process in the UAE follows a hierarchical structure involving various authorities, starting with federal regulations and extending to emirate-level bodies like the DOH. Additionally, there are healthcare-free zones in Dubai with their own regulatory bodies and criteria.

Competitive Landscape

Key Players

Otsuka Pharmaceutical Co., Ltd
AceLink Therapeutics, Inc
Reata Phrmaceuticals
Exelixis , Inc
Sanofi
Galapagos NV
Regulus Therapeutics
Palladio Biosciences
Xortx Therapeutics, Inc
Pano Therapeutics, Inc

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Segmentation

By Treatment

Pain & Inflammation Treatment
Kidney Stone Treatment
Urinary Tract Infection Treatment
Kidney Failure Treatment

By Route of Administration

Oral
Parenteral
Others

By End User

Hospitals
Speciality Clinics
Surgical Centres
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.